Eliem Therapeutics

Youtube Subscribe

Open: 3.22 Close: 2.98 Change: -0.24

You don't have time to read all about Eliem Therapeutics. An AI summarizes all the information for you.

The game is changing. There is a new strategy to evaluate Eliem Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Eliem Therapeutics are: GAAP, Eliems, Eliem, Therapeutics, Inc, ELYM, EPS, …

Concept Map

Semantic Network

Stock Summary

Eliem Therapeutics, Inc. focuses on developing therapies for neuronal excitability disorders. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, in preclinical for the treatment of.

Today's Summary

Eliem Therapeutics Inc. (ELYM) GAAP EPS of -$0.84 (NASDAQ:ELYM): Q1 GAAP eps of - $0.85. Eliems presented initial preclinical data from ETX-123, Eliems lead Kv7 program.

Today's News

Eliem Therapeutics Inc. (ELYM) GAAP EPS of -$0.84 (NASDAQ:ELYM): Q1 GAAP eps of - $0.85. Eliems presented initial preclinical data from ETX-123, Eliems lead Kv7 program.

Stock Profile

"Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington."

Keywords

How much time have you spent trying to decide whether investing in Eliem Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Eliem Therapeutics are: GAAP, Eliems, Eliem, Therapeutics, Inc, ELYM, EPS, and the most common words in the summary are: therapeutic, pharmaceutical, pharma, bioscience, biopharma, biotech, biotechnology, . One of the sentences in the summary was: Eliems presented initial preclinical data from ETX-123, Eliems lead Kv7 program.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #pharma #bioscience #biopharma #biotech #biotechnology.

Read more →

Youtube Subscribe

---